Giuliano Antoniol

Giuliano Antoniol

Auto-generated profile, based on publicly available information

Giuliano Antoniol

Polytechnique Montréal, Montréal, Québec, Canada

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 February 2025 in Empirical Software Engineering
Verified
Journal Article
Closed access
PDF file
FTFlorian Tambon
Florian Tambon
AMArghavan Moradi-Dakhel
Arghavan Moradi-Dakhel
ANAmin Nikanjam
Amin Nikanjam
FKFoutse Khomh
Foutse Khomh
MDMichel C. Desmarais
Michel C. Desmarais
GAGiuliano Antoniol
Giuliano Antoniol

10 April 2022 in Automated Software Engineering
Verified
Journal Article
Closed access
PDF file
FTFlorian Tambon
Florian Tambon
GLGabriel Laberge
Gabriel Laberge
LALe An
Le An
ANAmin Nikanjam
Amin Nikanjam
PMPaulina Stevia Nouwou Mindom
Paulina Stevia Nouwou Mindom
FLFrançois Laviolette
François Laviolette

29 November 2023 in Empirical Software Engineering
Verified
Journal Article
Closed access
PDF file
FTFlorian Tambon
Florian Tambon
ANAmin Nikanjam
Amin Nikanjam
LALe An
Le An
FKFoutse Khomh
Foutse Khomh
GAGiuliano Antoniol
Giuliano Antoniol

11 October 2022 in Cancers
Verified
Journal Article
Open access
PDF file
FCFrancesca Carlino
Francesca Carlino
ADANNA DIANA
ANNA DIANA
AVAnna Ventriglia
Anna Ventriglia
APAntonio Piccolo
Antonio Piccolo
CMCarmela Mocerino
Carmela Mocerino
MOMichele Orditura
Michele Orditura
Background: Approximately 45–50% of breast cancers (BCs) have a HER2 immunohistochemical score of 1+ or 2+ with negative in situ hybridization, defining the “HER2-low BC” subtype. No anti-HER2 agents are currently approved for this subgroup in Europe, where treatment is still determined by HR expression status. In this study, we investigated the prognostic significance of HER2-low status in HR+/HER2- metastatic BC (MBC) patients treated with endocrine therapy (ET) plus palbociclib as first line. Methods: We conducted a retrospective study including 252 consecutive HR+/HER2- MBC patients who received first-line ET plus palbociclib at six Italian Oncology Units between March 2016 and June 2021. The chi-square test was used to assess differences in the distribution of clinical and pathological variables between the HER-0 and HER2-low subgroups. Survival outcomes, progression-free survival (PFS) and overall survival (OS), were calculated by the Kaplan–Meier method, and the log-rank test was performed to estimate the differences between the curves. Results: A total of 165 patients were included in the analysis: 94 (57%) and 71 (43%) patients had HER2-0 and HER2-low disease, respectively. The median age at treatment start was 64 years. No correlation between patients and tumor characteristics and HER2 status was found. Median PFS (mPFS) for the entire study cohort was 20 months (95% CI,18–25 months), while median OS (mOS) was not reached at the time of analysis. No statistically significant differences, in terms of PFS (p = 0.20) and OS (p = 0.1), were observed between HER2-low and HER2-0 subgroups. Conclusions: In our analysis, HR+ MBC patients with low HER2 expression who received first-line treatment with ET plus Palbociclib reported no statistically different survival outcomes compared to HER2-0 patients. Further prospective studies are needed to confirm the clinical role of HER2 expression level.

19 December 2015 in Empirical Software Engineering
Verified
Journal Article
Closed access
PDF file
WWWei Wu
Wei Wu
FKFoutse Khomh
Foutse Khomh
BABram Adams
Bram Adams
YGYann-Gaël Guéhéneuc
Yann-Gaël Guéhéneuc
GAGiuliano Antoniol
Giuliano Antoniol

2 March 2018 in Empirical Software Engineering
Verified
Journal Article
Closed access
PDF file
RSRubén Saborido
Rubén Saborido
RMRodrigo Morales
Rodrigo Morales
FKFoutse Khomh
Foutse Khomh
YGYann-Gaël Guéhéneuc
Yann-Gaël Guéhéneuc
GAGiuliano Antoniol
Giuliano Antoniol